The 2013 NCCN Case Manager Webinar Series will consist of six live webinars on the topics of Acute Lymphocytic Leukemia (ALL), Biomarkers, Colorectal Cancer, Metastatic Prostate Cancer, Multiple Myeloma, and Palliative Care.

The 2013 NCCN Case Manager Webinar Series will consist of six live webinars on the topics of Acute Lymphocytic Leukemia (ALL), Biomarkers, Colorectal Cancer, Metastatic Prostate Cancer, Multiple Myeloma, and Palliative Care.

The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies. The Revised International Prognostic Scoring System (IPSS-R) provides a recently refined method for clinically evaluating the prognosis of patients with MDS.

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin’s Lymphoma (NHL) and provide a discussion of the clinical evidence that support the updates.

Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive lymphoma that confers a poor prognosis with current treatment strategies. Given the rarity of this disease, prospective randomized trials are limited, andthus a standard validated treatment strategy is lacking.

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances.

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma.

This recorded webinar is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Acute Myeloid Leukemia (AML).

This webinar is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Acute Myeloid Leukemia (AML).

This information was originally presented on September 15, 2012, at the NCCN 7^th Annual Congress: Hematologic Malignancies™ held in New York, New York.